We examined whether Pep#3(QYI) can induce epitope-specific CD8+ T cells in HLA-A24+ patients with HM (Supplementary Table 2), who represent a high-risk group that may be susceptible to COVID-19 due to immune-cell dysfunction related to disease progression or chemotherapy. The gene discussed is CD8A; the disease is COVID-19.